This study focuses on Heart Failure with Preserved Ejection Fraction, a condition where the heart’s ability to pump blood remains normal, but the heart has trouble filling with blood between beats. The study examines the effectiveness of two medications: spironolactone and eplerenone, which are drugs that help manage fluid levels in the body and reduce strain on the heart.
The purpose of this research is to determine if adding either spironolactone or eplerenone to standard treatment helps reduce hospitalizations due to heart failure and prevents deaths from heart-related causes. The medications will be taken by mouth daily, with doses up to 50 milligrams, and the treatment period may last up to 120 days.
During the study, participants will receive either one of these medications along with their usual heart failure treatments, or continue with their usual treatments alone. The study uses a registry-based approach, which means it collects information about patients’ health outcomes as part of their regular medical care.



Sweden